• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    CMC Pharmaceuticals

    Quotient Sciences

    Syngene International Ltd.

    LOTTE BIOLOGICS

    Lannett CDMO
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    CMC Pharmaceuticals

    Quotient Sciences

    Syngene International Ltd.

    LOTTE BIOLOGICS

    Lannett CDMO
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The “Greening” of Solid Dosage Form Manufacturing

    Going “green” can mean saving big bucks for pharma manufacturers.

    The “Greening” of Solid Dosage Form Manufacturing
    Emil W. Ciurczak, DoraMaxx Consulting11.20.19
    Over the past few years, I have lauded PAT (Process Analytical Technology), QbD (Quality by Design), and, of course CM (Continuous Manufacturing) as means to producing faster, less expensive, and safer drug products. What hasn’t been emphasized is the environmental effects of “better” manufacturing. Environmental matters are a large arena, so I will attempt to break down the areas where process analyses and control will help. The fact is that “going green,” in many cases, also means saving big bucks.

    Warehouse and production space
    On any given production site, the largest footprint is from the warehouses. Warehouses for raw materials, intermediate products, final products, and packaged products, ready to ship. When I worked at Merck (1991-2), West Pont, PA, I was able to walk across campus for whatever purpose. When I visited in 2005, I needed to drive to get somewhere in a reasonable time. The reason? Mainly warehouses and some labs had been constructed.

    I cannot directly address the cost per square foot of lighting and heating/air conditioning (HVAC), but assume we can cut at least 50% of our lighting and HVAC costs by not having to store intermediate (in-process) samples while waiting for either an analysis or piece of production equipment to be freed (cleaned and approved) for use in the next step of the process.

    Loss from transfer
    When the dry raw materials are transferred from storage and poured/scooped into a blender, some material is lost. When the blend is transferred to containers to another holding area to a granulator, more material is lost. During and after granulation (transfer), more is lost. In short, every time a powder blend is transferred from container to container a percentage is lost. When each process unit is washed, there is a volume of water, contaminated with detergent and API, washing down the drain.

    Cost of traditional analysis
    There are four major areas of expense: lab space, equipment, personnel, and chemicals. Let’s take a closer look at all four areas:

    1. Laboratory space. When designing and expanding the lab space, we need to include the expenses of all utilities (water, electric, gasses, and HVAC). One of the most expensive rooms to construct in a Pharma company is the lab. Many meters of gas, vacuum, and water pipes are required, plus multiple electrical outlets per section often with voltage smoothing equipment, sinks, air hoods, and so forth, are also needed.

    Also needed is the ancillary storage of solvents and chemicals in “explosion-proof” environments, which means more “brick and mortar” construction and ventilation. This means more space, electrical power, etc., all of which drive up costs.

    2. Equipment. No matter which manner of analysis a company chooses for routine analysis, capital purchases must be made. For this example, I will just compare a typical HPLC units with an NIR-based on-line (commercially available) unit.

    a. For the HPLC, a fully automated unit, capable of 30-50 samples over a 24-hour period, could cost between $35-50,000 (excluding columns, sample vials, etc.), ignoring IQ/OQ/PQ (necessary for any unit, often performed by the manufacturer). Operational costs are listed below.

    b. For an in-line NIRS unit, the cost would be around $100,000. This unit would be capable of analyzing whole capsules or tablets—for ID of API, content uniformity, and prediction of dissolution times—at a rate of 100,000 units per hour.

    c. Assuming a 3-5,000,000 tablet batch, the HPLC would be (destructively) measuring 0.007 to 0.004% of the batch for uniformity, while the NIR unit would be measuring (non-destructively) 100% of the batch using a blast of compressed air/nitrogen to eliminate any OOS sample.

    d. One of the most under-estimated time costs is the length of time needed for an HPLC assay. For illustration:
    i. Sample(s) must be gathered from production locale.
    ii. Label and transport the samples to QC.
    iii. Sign-in the samples and assign them to an analyst.
    iv. The analyst then prepares standards, performs sample preparation (grind, dissolve, filter, pipette into vials).
    v. Condition the HPLC, acquire computer files, place vials into unit and begin (15-20 min/sample).
    vi. Supervisor checks chromatograms for errors, OK’s the results, assuming a repeat is not needed, and releases or fails the batch (“failure” may just mean repeating a larger number of samples).
    vii. So, an HPLC assay without dissolution testing approaches one day in duration; the NIR time per sample is roughly 10 milliseconds, with no sample preparation.

    3. Personnel. While the actual analytical instruments may be automated, they still need personnel to do the paperwork, sample preparation, solvent/mobile phase preparation, set-up and break-down of columns, etc. Under normal conditions, one analyst is assigned or uses one HPLC. The number of lots run per day per unit will vary on the make and model as well as the difficulty of sample preparation (often, up to one hour or more), so the number of LC units needed to service a busy company will vary. In HPLC, there are both operators and maintenance personnel, while for in/at-line analysis units, the technical personnel are both operators and maintainers of the hardware.

    4. Chemicals, disposables. The cost of analysis can be estimated on an assay-by-assay basis:

    a. Assuming a single HPLC assay takes:
    i. 0.5 hour to obtain, label, and assign a sample.
    ii. 0.5 to 1.0 hour to prepare the sample for injection, taking between 250mL to 500mL of solvent per sample, normally ~50% organic solvent.
    iii. Between 10 to 30 minutes elution time per sample.
    iv. At 1.0 to 1.5 mL/min of mobile phase, each sample could use 10 to 45mL of solvent, per sample.

    b. The cost of one sample can then be estimated, if only for the expendables, ignoring HVAC and salaries of the people doing the work.
    i. Assume that HPLC grade solvents may cost $25-$50 per liter.
    ii. For a single sample, the cost could be (low vs. high)

    1. 1.0mL/min x 10 min x $25/L x 1.0L/1000mL x 50% = $0.13 (low)

    2. 1.5mL/min x 15 min x $50/L x 1.0L/1000mL x 50% = $1.13 (hi)
    iii. If a content uniformity were performed (10 samples, pre- and post-standards), we can “spend” $1.13/sample x 22 samples (and standards) = $24.75 in solvent used.
    iv. Add to that the cost and time of sample prep and the cost per sample increases even more.
    v. And, unless times have changed, it costs more to (legally) dispose of the solvents than to purchase them.

    c. Assume 50-60 lots of drug per week (with no re-runs or errors):
    i. For the short/fast runs; $0.13 x 22 samples x 50 lots = $143 in solvents.
    ii. For long/slower runs; $1.13 x 22 samples x 60 lots = $191.60 in solvents, alone.
    iii. The cost of disposal must include storage, transport, paperwork, fees for storage at final site, etc. Aside from all steps having toxic chemicals and chance of spillage or human exposure, double the cost per assay.

    d. The exact cost of filters, injection vials, and columns will vary, but could well equal the cost of solvents and may be more stressful on disposal sites than the actual solvents (which, in some cases may be recycled or burned).

    e. While the exact number of calibrated glassware needed varies, the need for washing and storing them must be considered: washing requires water (cost plus usage), detergents, and drying (often heated). All use electricity, which is often generated from fossil fuel… not to mention burden on the sewage system.

    Cost of quality
    Clearly, something as drastic as a product recall would be financially disastrous—cost of product, transportation costs, off-the-shelf-time, reputation diminishing, fines from FDA—but would also exacerbate the environmental problems. If nothing else, the replacement batch would have the same losses as the recalled batch (process losses, transportation emissions, etc.) and the recalled batch would need to be safely destroyed and disposed. The disposed/destroyed lot also poses the same environmental problems as the rinse-water from equipment cleaning (or spillage of and/or improper handling of solvents), but on a much larger scale.

    The API might be recovered prior to disposal, but that involves more solvents, which will eventually need to be disposed of or allowed to evaporate. The former has the potential to contaminate groundwater while the latter is a clean air hazard.

    Observation and suggestion
    Moving from “traditional” batch-style production to a simple PAT-mode will alone speed up production and minimize losses both financially and environmentally. Adding QbD will make for fewer OOS batches, avoiding batch destruction or recall. When, and if, real-time release (in-line measurements of final product) is added, the cost saving goes up by far more—zero recalled batches and a massive avoidance of lab-based assays.

    More than a decade of accepted and successful submissions to the FDA and EMA have shown that end-of-process NIR (or Raman) monitoring can provide identification (verification of ID and level) of the API, API assay, content uniformity, and, for a bonus, dissolution predictions may be generated. All these save transportation (to the lab) time, solvents, columns, labor, etc.

    When you are ready for the “big time,” continuous manufacturing is the “trifecta” of all these savings. There would be no transfer losses (with cleaning pollution), no lab solvent usage (destructive assays and labor costs), and real-time release. As an added attraction, the “footprint” of the process will be a mere fraction of batch processing and the warehouses need not be built. A win-win-win for the company, patient, and environment. 


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • tablets
    • Capsules
    • equipment
    • vials
    Suggested For You
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Biopharma Over 20 Years Biopharma Over 20 Years
    German Pharma Benefiting From a Brexit Boost? German Pharma Benefiting From a Brexit Boost?
    Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future
    Vetio Animal Health Vetio Animal Health
    A Witness to the Growth of Outsourcing A Witness to the Growth of Outsourcing
    Highly Potent Expansions Highly Potent Expansions
    The Bioprocessing Trek The Bioprocessing Trek
    Quality Metrics Feedback Quality Metrics Feedback
    Changing the Face of CDMOs Changing the Face of CDMOs
    FDA Extends CRADA with CluePoints FDA Extends CRADA with CluePoints
    Northwest Biotherapeutics Expands Senior Management Team Northwest Biotherapeutics Expands Senior Management Team
    NIIMBL, FDA to Advance Innovation in Bio Manufacturing NIIMBL, FDA to Advance Innovation in Bio Manufacturing
    Merck to Build $650M Biomanufacturing Plant in NC Merck to Build $650M Biomanufacturing Plant in NC

    Related Buyers Guide Companies

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Softweb Solutions

      ...
      Micheal Jury, Marketing Manager 09.23.20

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19


    • German Pharma Benefiting From a Brexit Boost?

      German Pharma Benefiting From a Brexit Boost?

      Germany consolidates itself as world leader in pharma according to the CPhI Pharma Index.
      10.29.19

    • Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future

      ...
      10.28.19

    Loading, Please Wait..
    Breaking News
    • Univercells Expands into the U.S. With New Offices in Andover, MA
    • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    • Sanner Group Opens Second Manufacturing Facility in China
    • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Pharma Supply Chains: From Fragile to Agile
    • Overcoming Stressors in Knowledge Transfer
    • Innovations in Pharma Packaging
    • HPAPI Manufacturing Trends
    • Sustainable Packaging in Pharma: No Longer a Pipe Dream
    • Revolutionizing Pharma’s Supply Chain
    • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
    • Solving Pharma’s Underlying Rebate Leakage Problem
    • Advanced Manufacturing and a Roadmap to the Facility of the Future
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    AkzoNobel Shares Sustainable Architectural Solutions at Conference
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Stoelzle Glass Group Names New CEO
    Happi

    Latest Breaking News From Happi

    The Estée Lauder Companies Launches 2023 Breast Cancer Campaign
    BASF Personal Care Introduces New Cosmetic Ingredient
    Breakfast with Oral Care Benefits?
    Ink World

    Latest Breaking News From Ink World

    Siegwerk’s Climate Targets Validated by SBTi
    ROSS Offering Cost-Effective, Expertly Reconditioned Equipment
    Amcor plc Adds Lucrèce Foufopoulos-De Ridder to Board of Directors
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Centinel Spine prodisc System Surpasses 2,500-Implant Milestone
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More
    SCHOTT Strengthens Glass Substrate Portfolio

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login